PHARMACY CARE NICOTINE LOZENGES 4mg nicotine (as nicotine polacrilex) lozenge blister pack

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

nicotine polacrilex, Quantity: 26.66 mg (Equivalent: nicotine, Qty 4 mg)

MAH:

Orion Laboratories Pty Ltd T/A Perrigo Australia

INN:

Nicotine polacrilex

pharmaceutical_form:

Tablet, uncoated

composition:

Excipient Ingredients: aspartame; sodium alginate; xanthan gum; potassium bicarbonate; magnesium stearate; sodium carbonate; mannitol; Flavour

administration_route:

Buccal

units_in_package:

156, 120, 36, 168, 144, 96, 72, 108, 132

prescription_type:

Not Scheduled after consideration by Committee

therapeutic_indication:

Relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. Nicotine Lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. If possible, when stopping smoking, should be used in conjunction with behavioural support program.

leaflet_short:

Visual Identification: Cream/white embossed biconvex round tablet with a peppermint odour. Embossed with ?L873? on one face; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

authorization_status:

Licence status A

authorization_date:

2014-12-16